Addressing the authorization of orphan drugs will not fix reimbursement problems: The elephant is still in the room

Canadian Pharmacists Journal

Volumn 146, Issue 5, 2013, Pages 245-246

  Embrett, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

CLINICAL DECISION MAKING; COST CONTROL; DRUG COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; LONG TERM EXPOSURE; NOTE; PUBLIC-PRIVATE PARTNERSHIP; REIMBURSEMENT;

EID: 84890162545     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163513499127     Document Type: Note

References (4)

1. Romanow R. Building on values: the future of health care in Canada. 2002. Available: http://publications.gc.ca/collections/Collection/CP32-85-2002E.pdf (accessed July 4, 2013).
2. Kirby M, LeBreton M. The health of Canadians: the federal role, 2002. Available: www.parl.gc.ca/37/2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02vol6-e.htm (accessed July 4, 2013).
3. MacKinnon N, Ip I. The national pharmaceuticals strategy: rest in peace, revive, or renew? CMAJ 2009;180:801-3.
4. Embrett M, MacKinnon N. Qualitative evaluation of the Canadian Fabry Disease Initiative. Can Pharm J (Ott) 2012;145:136-41.